We attended the 2024 Global Leadership Workshop in Copenhagen with 3 members of the Swiss HAE Association.

We would like to thank the very good organization. The conference venue was also well chosen as it was right next to the airport. This meant that the journey to and from the airport was short as we had to leave very early on Sunday.

CSL Behring expects approval in Switzerland for the active ingredient Garadacimab by the end of 2024. If approved, patients will benefit from an auto-injector (prefilled pen) for convenient administration.